

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2017/009459 A2

(43) International Publication Date
19 January 2017 (19.01.2017)

(51) International Patent Classification:
C07K 16/18 (2006.01)

(21) International Application Number:
PCT/EP2016/066924

(22) International Filing Date:
15 July 2016 (15.07.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/193,356 16 July 2015 (16.07.2015) US
62/209,650 25 August 2015 (25.08.2015) US

(71) Applicant: **PROBIODRUG AG** [DE/DE]; Weinbergweg
22, 06120 Halle / Saale (DE).

(72) Inventors: **KLEINSCHMIDT, Martin**; Schillerstr. 25,
06114 Halle / Saale (DE). **RAHFLED, Jens-Ulrich**;
Grasemannweg 4, OT Roeblingen am See, 06317 Ge-
meinde Seegebiet Mansfelder Land (DE). **PIECHOTTA,**
Anke; Bernhardtstr. 20, 06120 Halle / Saale (DE).
SCHILLING, Stephan; Glockenweg 4, 06130 Halle /
Saale (DE). **GILLIES, Steven**; 47 Swanson Lane, Carlisle,
Massachusetts 01741 (US).

(74) Agent: **MAIKOWSKI & NINNEMAN PATENTAN-**
WÄLTE PARTNERSCHAFT MBB; 15 09 20, 10671
Berlin (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with (an) indication(s) in relation to deposited biological
material furnished under Rule 13bis separately from the
description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HUMANIZED ANTIBODIES

(57) Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A β N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A β N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.



WO 2017/009459 A2